Ilker Tinay (@itinay) header
Ilker Tinay (@itinay) profile picture

Prof. of Urology @atlas_intoffice | Director of Urologic Oncology @anadolusaglik | Board Member of Turkish Association of Urooncology @Uroonkoloji1999

Istanbul, TURKEY
Joined June 2013
Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)Photo by Ilker Tinay (@itinay)
Lots of publicity around the positive PIVOT-006 results. Much of the discussion has focused on the surveillance control arm which did not include current standard of care ie intravesical chemotherapy But let’s not forget something important: BCG has long been shown to be superior to intravesical chemotherapy, even in intermediate-risk NMIBC. A reminder from EORTC 30911. 🧵#SUO26
2
7
25
2,343
🚨 When Decipher & NCCN risk groups disagree for #ProstateCancer🚨 📖@CCR_AACR 👥 287,145 biopsy pts for molecular prevalence; DM assessed in 15,109 w/ NCCN high/very-high-risk 📊 Decipher score vs NCCN risk, + 4 adverse molecular features: TP53 mutant-like, PTEN loss, low AR activity, RB1 loss ✅Decipher showed 21% of NCCN low/favorable-intermediate pts to be high risk ✅ Decipher showed 33% of NCCN high-risk pts to be lower risk ✅ ≥1 adverse AMF + Decipher >0.60: predicted 5-yr distant met risk 17-25% vs 5% w/ favorable profile + Decipher ≤0.60 ⚠️ Retrospective cohort / correlative not randomized 🎯 TP53, PTEN loss and low AR activity drive most NCCN-Decipher discordance 🔗 doi.org/10.1158/1078-0432.CC… @UroOnc @urotoday @UrologyTimes @PCF_Science @DrSpratticus @Davicioni @angela_jia_
1
30
1
78
4,714
PROTEUS: A positive trial, but does every high-risk prostate cancer patient need intensification? 🤔 An interesting NEJM correspondence challenges how we interpret the PROTEUS results. 🔹 The benefit: MFS improved (HR 0.80; P = 0.02), with a 4.7% absolute gain at 5 years. 🔹 The controversy: PSMA PET-inclusive MFS was statistically significant, but conventional-imaging MFS was not (HR 0.84). 🔹 The authors' defense: Both analyses favour treatment; fewer conventional-imaging events limit statistical power. 🔹 Beyond statistics: Endpoint modification, unequal PSMA PET use, heterogeneous risk, positive surgical margins and treatment burden raise important questions. My takeaway: PROTEUS is positive, but OS benefit remains unproven. Patient selection, absolute benefit and toxicity matter. A positive trial ≠ Treat every patient. 📖 NEJM Correspondence, 12 Nov 2026 DOI: 10.1056/NEJMc2611613 #PROTEUS #ProstateCancer #Oncology #ClinicalTrials #MVOnco @OncoAlert @OncoDaily @larvol
11
30
2,836
Ilker Tinay retweeted
Coming soon...
2
14
2
55
3,337
Ilker Tinay retweeted
Published in the October 2026 issue of European Urology @EUPlatinum (Impact Factor: 29), this collaborative work was led by Roger Li @UrogerliMD, Can Aydogdu @CanDAydogdu, Laura Bukavina @LauraBukavinaMD A must-read for anyone interested in bladder cancer! Great honor to be part of this work.  @UroDocAsh @AndreaNecchi @apolo_andrea @SpiessPhilippe This comprehensive review provides an integrated overview of the pathology, molecular characteristics, and clinical management of major bladder cancer subtypes, including squamous, adenocarcinoma/glandular, micropapillary, sarcomatoid, plasmacytoid, nested, and small cell neuroendocrine carcinoma. These tumors are biologically heterogeneous, often clinically aggressive, and frequently understaged on transurethral resection, supporting consideration of early radical cystectomy in selected high-risk patients.   Importantly, treatment response varies substantially by histology. Small cell neuroendocrine carcinoma demonstrates the clearest benefit from platinum/etoposide-based chemotherapy, while other subtypes show variable responses to conventional systemic therapies. Molecular profiling reveals potentially actionable alterations, including ERBB2 in micropapillary carcinoma, CDH1 loss in plasmacytoid carcinoma, FGFR3 alterations in nested carcinoma, and TP53/RB1 alterations in small cell carcinoma. Emerging evidence also supports potential roles for immune checkpoint inhibitors and antibody-drug conjugates.   We emphasizes that variant bladder cancers should not be managed using a uniform approach. Accurate histologic classification, quantification of subtype components, and molecular profiling are increasingly important for personalized treatment and future subtype-specific clinical trials.   Full article available at authors.elsevier.com/c/1nL8w…
2
42
2
130
9,238
Ilker Tinay retweeted
No family history is not the same as no inherited risk. @Uroweb @ESTRO_RT @EANM_NucMed @OncoAlert @OpenMedicineHQ #EMUC26 @Ecastromarcos @NivenMehra
9
32
1,402
Proud to present our nationwide multicentre study by @Uroonkoloji1999 at #EMUC26 in Brussels Exploring two decades of evolving trends in neoadjuvant chemotherapy use and surgical approach of muscle-invasive bladder cancer across in Türkiye. #BladderCancer #UroOncology
1
21
787
🚨 PROTEUS substudy (@EUplatinum): perioperative apalutamide + ADT improves event-free survival vs radical prostatectomy alone in high-risk/locally advanced #prostatecancer, 🧵 1/3 🚨 👥 408 pts, high-risk localized or locally advanced PCa, fit for surgery 📊 Open-label phase 3 substudy, randomized 1:3 💊 Perioperative (neoadj + adj) apalutamide + ADT (n=102) vs RP alone (n=306) ⏱️ Median f/u 37.4 mo ⭐️Event = BCR or imaging-based recurrence ✅ 3-yr EFS 63% vs 41%, HR 0.38 (0.26-0.55), p<0.001 ✅ MFS by conventional or PSMA PET 87% vs 78%, HR 0.49 (0.26-0.90) ✅ But MFS by conventional imaging alone: similar, 94% vs 92% (p=0.5) ⚠️Caution in interpretation - See thread 👇 🔗 doi.org/10.1016/j.eururo.202… @PCFnews @PCF_Science @urotoday @UrologyTimes @TylerSbrt @renalandurology @Uroweb @JackAndrewsMD
6
29
1
84
7,950
mm pattern 4 on biopsy far superior predictor of prostate cancer outcome than stage, grade, PSA, cores. We show using mm criteria rather than "favorable intermediate risk" would increase the number of US men eligible for active surveillance by >50,000. bjui-journals.onlinelibrary.…
2
25
2
78
11,062
Ilker Tinay retweeted
PRACTICE CHANGING: #KEYNOTEB15/EV304- in #MIBC, periop EV/P led to sig EFS (NR v 48.5m, 24m EFS 79.4 v 66.2%, HR0.53; 0.41-0.7), OS (NR v NR, 24m estimated OS 86.9 v 81.3%, HR 0.65; 0.48-0.89), pCR  (55.8 v 32.5%) benefit v. neoadj gem/cis, supporting EV/P as SOC in this setting
1
5
1
12
8,466
Ilker Tinay retweeted
PROTEUS enrolled a “real” high risk cohort. NCCN criteria are insufficient here. #ASCO26
2
5
25
3,103
Ilker Tinay retweeted
Presented at #ASCO26: In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: nej.md/3RuNe00 Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW @ASCO
1
81
16
179
53,722
🚨Testosterone replacement therapy after surgery for #prostatecancer🚨 @JAMAInternalMed ⭐️SPIRIT trial 📊 RCT, n=136, low/int-grade PCa, post-RP, hypogonadal men ⏱️ TRT started ≥2 yrs post-RP w/ undetectable PSA 💉 12 wks testosterone vs placebo ✅ ↑ sexual activity (+0.9 events/day), desire, lean mass, VO₂ peak 🛡️ ZERO biochemical recurrences ⚠️ Short-term, proof-of-concept. 👉Bigger/longer trials including patients with higher-risk disease needed @PCFnews @PCF_Science @urotoday @renalandurology @UrologyTimes 🔗shorturl.at/IzRyw
7
46
3
165
16,909
Kongremiz 17–21 Kasım 2027 tarihleri arasında Regnum Carya Otel, Antalya’da gerçekleştirilecektir. Mesleki gelişim, bilgi paylaşımı ve bilimsel etkileşimin ön planda olacağı bu kongrede sizleri aramızda görmekten onur duyacağız. #Üroonkoloji #ÜroonkolojiKongresi #Bilim
6
6
568
BRCA1 and BRCA2 pathogenic variants increase the risk of four less common cancer types - ESMO Open esmoopen.com/article/S2059-7… @OncoAlert
1
34
1
107
9,082
Ilker Tinay retweeted
🔥 POISE-3 Urology published in European Urology 🚨 In the largest randomized placebo-controlled #urology analysis of #TranexamicAcid (TXA), #TXA reduced major #bleeding risk by 37% (from 9.5% to 6.1%) with no clear increase in #thrombosis More at sciencedirect.com/science/ar… #EBM
2
40
3
128
21,535
Ilker Tinay retweeted
A new standard of care in the peri-op management of muscle invasive #bladdercancer ! No need chemo in this setting anymore!🚨‼️ #GU26 @ASCO @OncoAlert @MattGalsky @DrYukselUrun @OncoBellmunt @BourlonMaite @PGrivasMDPhD @drenriquegrande @shilpaonc @OncBrothers @DrChoueiri #Cancer #oncology
3
26
3
63
9,300
🤖🆚🗡️ Robotic vs open partial nephrectomy for complex kidney tumors 👏Tested in an RCT (OpeRa trial) @Annals_Oncology 🔑🔑 Takeaways: ⚖️ 30-day complications: no significant difference (RAPN 37% vs OPN 46%) ⏱️ RAPN = longer OR + warm ischemia time 🏥 RAPN = shorter hospital stay 💊 Less opioids, less pain 😊 Better QoL through POD30 ⭐️ RAPN not clearly safer, but easier on patients in the short term — even for intermediate/high-complexity tumors 🔗shorturl.at/dUbgk @urotoday @renalandurology @UrologyTimes
3
14
43
4,602
⚡️ @EurUrolOncol: Regional node–positive bladder cancer (cN+) is heterogeneous and still lacks phase III evidence. Retrospective series support multimodal management: cisplatin-based induction chemotherapy plus consolidative RC, with best outcomes when ypN0 is achieved. #BladderCancer @OncoAlert europeanurology.com/article/…
2
25
60
3,842